Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial.

Saxon RR, Chervu A, Jones PA, Bajwa TK, Gable DR, Soukas PA, Begg RJ, Adams JG, Ansel GM, Schneider DB, Eichler CM, Rush MJ.

J Vasc Interv Radiol. 2013 Feb;24(2):165-73; quiz 174. doi: 10.1016/j.jvir.2012.10.004. Epub 2013 Jan 28.

PMID:
23369553
2.

Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease).

Lammer J, Zeller T, Hausegger KA, Schaefer PJ, Gschwendtner M, Mueller-Huelsbeck S, Rand T, Funovics M, Wolf F, Rastan A, Gschwandtner M, Puchner S, Ristl R, Schoder M.

J Am Coll Cardiol. 2013 Oct 8;62(15):1320-7. doi: 10.1016/j.jacc.2013.05.079. Epub 2013 Jul 10.

3.

Heparin-bonded stent-graft for the treatment of TASC II C and D femoropopliteal lesions: the Viabahn-25 cm trial.

Zeller T, Peeters P, Bosiers M, Lammer J, Brechtel K, Scheinert D, Rastan A, Noory E, Beschorner U.

J Endovasc Ther. 2014 Dec;21(6):765-74. doi: 10.1583/14-4790R.1.

PMID:
25453876
4.

Randomized controlled trial comparing the safety and efficacy between the FUSION BIOLINE heparin-coated vascular graft and the standard expanded polytetrafluoroethylene graft for femoropopliteal bypass.

Lumsden AB, Morrissey NJ; Comparison of Safety and Primary Patency Between the FUSION BIOLINE Heparin-Coated Vascular Graft and EXXCEL Soft ePTFE (FINEST) Trial Co-investigators.

J Vasc Surg. 2015 Mar;61(3):703-12.e1. doi: 10.1016/j.jvs.2014.10.008. Erratum in: J Vasc Surg. 2015 May;61(5):1382.

5.

Randomized comparison of ePTFE/nitinol self-expanding stent graft vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease.

McQuade K, Gable D, Hohman S, Pearl G, Theune B.

J Vasc Surg. 2009 Jan;49(1):109-15, 116.e1-9; discussion 116. doi: 10.1016/j.jvs.2008.08.041. Epub 2008 Nov 22.

6.

Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease.

Geraghty PJ, Mewissen MW, Jaff MR, Ansel GM; VIBRANT Investigators.

J Vasc Surg. 2013 Aug;58(2):386-95.e4. doi: 10.1016/j.jvs.2013.01.050. Epub 2013 May 13.

7.

Heparin-bonded expanded polytetrafluoroethylene vascular graft for femoropopliteal and femorocrural bypass grafting: 1-year results.

Bosiers M, Deloose K, Verbist J, Schroë H, Lauwers G, Lansink W, Peeters P.

J Vasc Surg. 2006 Feb;43(2):313-8; discussion 318-9.

8.

Heparin-bonded expanded polytetrafluoroethylene femoropopliteal bypass grafts outperform expanded polytetrafluoroethylene grafts without heparin in a long-term comparison.

Samson RH, Morales R, Showalter DP, Lepore MR Jr, Nair DG.

J Vasc Surg. 2016 Sep;64(3):638-47. doi: 10.1016/j.jvs.2016.03.414. Epub 2016 Apr 29.

PMID:
27139782
9.
10.

Long-term patency and clinical outcome of the Viabahn stent-graft for femoropopliteal artery obstructions.

Saxon RR, Coffman JM, Gooding JM, Ponec DJ.

J Vasc Interv Radiol. 2007 Nov;18(11):1341-9; quiz 1350.

PMID:
18003983
11.

Four-year randomized prospective comparison of percutaneous ePTFE/nitinol self-expanding stent graft versus prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease.

McQuade K, Gable D, Pearl G, Theune B, Black S.

J Vasc Surg. 2010 Sep;52(3):584-90; discussion 590-1, 591.e1-591.e7. doi: 10.1016/j.jvs.2010.03.071.

12.

Superiority of stent-grafts for in-stent restenosis in the superficial femoral artery: twelve-month results from a multicenter randomized trial.

Bosiers M, Deloose K, Callaert J, Verbist J, Hendriks J, Lauwers P, Schroë H, Lansink W, Scheinert D, Schmidt A, Zeller T, Beschorner U, Noory E, Torsello G, Austermann M, Peeters P.

J Endovasc Ther. 2015 Feb;22(1):1-10. doi: 10.1177/1526602814564385.

PMID:
25775672
13.

Early results with the use of heparin-bonded stent graft to rescue failed angioplasty of chronic femoropopliteal occlusive lesions: TASC D lesions have a poor outcome.

Kuhan G, Abisi S, Braithwaite BD, MacSweeney ST, Whitaker SC, Habib SB.

Cardiovasc Intervent Radiol. 2012 Oct;35(5):1023-8. Epub 2012 Jun 14.

PMID:
22696009
14.

Long-term results of ePTFE stent-graft versus angioplasty in the femoropopliteal artery: single center experience from a prospective, randomized trial.

Saxon RR, Coffman JM, Gooding JM, Natuzzi E, Ponec DJ.

J Vasc Interv Radiol. 2003 Mar;14(3):303-11.

PMID:
12631634
15.

Excimer laser with adjunctive balloon angioplasty and heparin-coated self-expanding stent grafts for the treatment of femoropopliteal artery in-stent restenosis: twelve-month results from the SALVAGE study.

Laird JR Jr, Yeo KK, Rocha-Singh K, Das T, Joye J, Dippel E, Reddy B, Botti C, Jaff MR.

Catheter Cardiovasc Interv. 2012 Nov 1;80(5):852-9. doi: 10.1002/ccd.23475. Epub 2012 Mar 15.

PMID:
22422738
16.

Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.

Zeller T, Rastan A, Macharzina R, Tepe G, Kaspar M, Chavarria J, Beschorner U, Schwarzwälder U, Schwarz T, Noory E.

J Endovasc Ther. 2014 Jun;21(3):359-68. doi: 10.1583/13-4630MR.1.

PMID:
24915582
17.

Heparin-bonded ePTFE grafts compared with vein grafts in femoropopliteal and femorocrural bypasses: 1- and 2-year results.

Daenens K, Schepers S, Fourneau I, Houthoofd S, Nevelsteen A.

J Vasc Surg. 2009 May;49(5):1210-6. doi: 10.1016/j.jvs.2008.12.009.

18.

Sustained benefit at 2 years for covered stents versus bare-metal stents in long SFA lesions: the VIASTAR trial.

Lammer J, Zeller T, Hausegger KA, Schaefer PJ, Gschwendtner M, Mueller-Huelsbeck S, Rand T, Funovics M, Wolf F, Rastan A, Gschwandtner M, Puchner S, Beschorner U, Ristl R, Schoder M.

Cardiovasc Intervent Radiol. 2015 Feb;38(1):25-32. doi: 10.1007/s00270-014-1024-9. Epub 2014 Dec 5. Erratum in: Cardiovasc Intervent Radiol. 2015 Jun;38(3):779-80.

PMID:
25472936
19.

French multicenter experience with the GORE TIGRIS Vascular Stent in superficial femoral and popliteal arteries.

Sibé M, Kaladji A, Boirat C, Cardon A, Chaufour X, Bossavy JP, Saint-Lebes B.

J Vasc Surg. 2017 May;65(5):1329-1335. doi: 10.1016/j.jvs.2016.11.056. Epub 2017 Feb 20.

PMID:
28222987
20.

Results with Viabahn-assisted subintimal recanalization for TASC C and TASC D superficial femoral artery occlusive disease.

Schneider JR, Verta MJ, Alonzo MJ, Hahn D, Patel NH, Kim S.

Vasc Endovascular Surg. 2011 Jul;45(5):391-7. doi: 10.1177/1538574411405548. Epub 2011 Jun 12.

PMID:
21669863

Supplemental Content

Support Center